163 related articles for article (PubMed ID: 8144931)
1. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
Marincola FM; Ettinghausen S; Cohen PA; Cheshire LB; Restifo NP; Mulé JJ; Rosenberg SA
J Immunol; 1994 Apr; 152(7):3500-13. PubMed ID: 8144931
[TBL] [Abstract][Full Text] [Related]
2. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
3. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells.
Sadanaga N; Nagoshi M; Lederer JA; Joo HG; Eberlein TJ; Goedegebuure PS
J Immunother; 1999 Jul; 22(4):315-23. PubMed ID: 10404433
[TBL] [Abstract][Full Text] [Related]
4. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.
Restifo NP; Spiess PJ; Karp SE; Mulé JJ; Rosenberg SA
J Exp Med; 1992 Jun; 175(6):1423-31. PubMed ID: 1588273
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy.
Goedegebuure PS; Zuber M; Leonard-Vidal DL; Burger UL; Cusack JC; Chang MP; Douville LM; Eberlein TJ
Surg Oncol; 1994 Apr; 3(2):79-89. PubMed ID: 7952395
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
7. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
9. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
Shu S; Chou T; Rosenberg SA
J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
11. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.
Peng L; Krauss JC; Plautz GE; Mukai S; Shu S; Cohen PA
J Immunol; 2000 Dec; 165(12):7116-24. PubMed ID: 11120842
[TBL] [Abstract][Full Text] [Related]
12. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
Sakai K; Chang AE; Shu S
Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
Chou T; Bertera S; Chang AE; Shu S
J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
[TBL] [Abstract][Full Text] [Related]
14. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
Nastala CL; Edington HD; McKinney TG; Tahara H; Nalesnik MA; Brunda MJ; Gately MK; Wolf SF; Schreiber RD; Storkus WJ
J Immunol; 1994 Aug; 153(4):1697-706. PubMed ID: 7913943
[TBL] [Abstract][Full Text] [Related]
15. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific cytokine release by donor T cells induces an effective host anti-tumor response through recruitment of host naive antigen presenting cells.
Nagoshi M; Sadanaga N; Joo HG; Goedegebuure PS; Eberlein TJ
Int J Cancer; 1999 Jan; 80(2):308-14. PubMed ID: 9935215
[TBL] [Abstract][Full Text] [Related]
17. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
[TBL] [Abstract][Full Text] [Related]
19. Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes.
Alexander RB; Rosenberg SA
J Immunother (1991); 1991 Dec; 10(6):389-97. PubMed ID: 1768672
[TBL] [Abstract][Full Text] [Related]
20. Role of tumor necrosis factor species in the sequence-dependent effects of interleukin-2--tumor necrosis factor immunotherapy in mice: implications for preclinical cytokine testing.
Owen-Schaub LB; Santee SM; Winkelhake JL; Zimmerman RJ
J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):1-10. PubMed ID: 8110725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
